A Study to Investigate PK, Safety, Tolerability of Cefepime-enmetazobactam in Pediatric Participants With cUTI

Single Group Phase 2 Study to Investigate Pharmacokinetics, Safety and Tolerability of Cefepime-Enmetazobactam Administered by IV Over 2 Hr in Male or Female Participants From Birth to Less Than 18 Years of Age Hospitalised With cUTI

This phase 2 study is part of regulatory commitments in the United States (PSP) and Europe (PIP) to evaluate cefepime-enmetazobactam in paediatric participants with cUTI to support extension of the indication for cefepime-enmetazobactam to children with cUTI.

Study Overview

• Status: Recruiting
• Conditions: Complicated Urinary Tract Infection
• Intervention / Treatment: Drug: cefepime and enmetazobactam combination

Detailed Description

The purpose of this study is to evaluate the blood concentrations and safety of the fixed dose combination of 2 drugs, cefepime with enmetazobactam administered intravenously in participants aged from birth to less than 18-years of age, hospitalised with a complicated urinary tract infection.

The treatment duration will be between 3 and 7 days, depending on the time needed for disappearance of signs and symptoms of the infection.

The participant will need to be hospitalised at least during the treatment administration period. After the last administration of cefepime and enmetazobactam, there will be the end of treatment visit (EOT), then 2 follow-up visits at 7 days (Test of Cure (TOC)), then 14 days (Late Follow-up (LFU)) after the end of treatment visit. The End of study Visit (EOS) will be conducted via telephone call (or a visit deemed necessary as per the investigator) 28 days after the EOT visit. The participants may be discharged from hospital at the discretion of the investigator after the end of treatment visit but will be required to return to the hospital for the 2 follow-up visits.

• Study Type: Interventional
• Enrollment (Estimated): 40
• Phase: Phase 2

Contacts and Locations

Study Locations

• Czechia
  • Hradec Králové, Czechia, 500 05
    • Recruiting
    • Fakultní nemocnice Hradec Králové -Ústav klinické biochemie a diagnostiky
    • Contact: Sylva Skalova, MD; Phone Number: 00 420 495 832 840; Email: sylva.skalova@fnhk.cz
• France
  • Toulouse, France
    • Not yet recruiting
    • Hopital des Enfants
    • Contact: Lucas Percheron, MD; Phone Number: 00 335 67 77 10 95; Email: percheron.l@chu-toulouse.fr
• Hungary
  • Debrecen, Hungary
    • Not yet recruiting
    • Debreceni Egyetem Klinikai Központ Gyermekgyógyászati Klinika
    • Contact: Tamás Szabó, MD; Phone Number: 00 3630 5769 835; Email: szabotamas@med.unideb.hu
• Poland
  • Łomianki, Poland
    • Recruiting
    • SZPZOZ im. Dzieci Warszawy w Dziekanowie Lesnym
    • Contact: Joanna Samotyjek; Phone Number: 00 486 032 81617; Email: joanna.samotyjek@szpitaldziekanow.pl
• Slovakia
  • Bratislava, Slovakia
    • Not yet recruiting
    • Národný ústav detských chorôb (NÚDCH)
    • Contact: Ludmila Podradska
• Spain
  • Madrid, Spain
    • Not yet recruiting
    • Hospital Universitario La Paz
    • Contact: Alejandro Zarauza; Phone Number: 00 34 69 99 48226; Email: alexzarauzasant@gmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Participant must be from birth to <18 years of age. Participants up to 2 months must have been born at term or preterm with a gestational age ≥32 weeks.
• Written informed consent from parent(s) or other legally acceptable representative(s), and informed assent from participant (if age appropriate according to local regulations).

• If female and has reached menarche, or has reached Tanner stage 3 development, (even if not having reached menarche) the participant is authorized to participate in this clinical study if the following criteria are met:

  1. Participant has a negative urine and/or serum human chorionic gonadotropin test at screening visit. As serum tests may miss an early pregnancy, relevant menstrual history, and sexual history, including methods of contraception, should be considered
  2. Participant agrees to avoid conception from the time of screening until 7 days after receipt of study intervention and agrees not to attempt pregnancy from the time of screening until 7 days after EOT with study intervention, and participant agrees to follow guidelines received regarding continuation of abstinence, initiation of abstinence or about allowed contraception, and
  3. Participant reports sexual abstinence for the prior 3 months or reported the use of at least 1 of the acceptable methods of contraception, including an intrauterine device (with copper banded coil), levonorgestrel intrauterine system or regular medroxyprogesterone injections, or participant agrees to initiate sexual abstinence from the time of screening until 7 days after end of treatment (EOT) with study intervention.
• Participant has a clinically suspected and/or bacteriologically documented complicated urinary tract infection (cUTI) or acute pyelonephritis judged by the investigator to require the participant to be hospitalized for treatment with intravenous (i.v.) therapy.
• The causative pathogen is confirmed or suspected to be susceptible to cefepime-enmetazobactam.

• Participant has pyuria, defined as dipstick analysis positive for leukocyte esterase OR:

  1. If ≥1 year of age: White blood cell (WBC) count >10 cells/µL in unspun urine or ≥10 cells/high power field in spun urine.
  2. If <1 year of age: WBC count >5 cells/µL in unspun urine or ≥5 cells/high power field in spun urine.

• Participant demonstrates clinical signs and/or symptoms of either acute pyelonephritis or cUTI at the Screening Visit, as defined by the following criteria:

  a. For pyelonephritis, participants must have at least 2 of the following new or worsening signs and/or symptoms: i. If 0 to <2 years of age:

  • Fever (as defined by the investigator)
  • Failure to thrive
  • Recent weight loss
  • Irritability
  • Poor feeding
  • Lack of normal level of activity
  • Abdominal tenderness on physical examination
  • Vomiting ii. If 2 to <18 years of age:
  • Fever (as defined by the investigator)
  • Dysuria
  • Urinary urgency
  • Urinary frequency
  • New-onset urinary incontinence
  • Suprapubic pain, flank pain, or abdominal pain
  • Suprapubic tenderness or CVA tenderness on physical examination

  • Nausea or vomiting OR

    b. For cUTI, participants must have at least 2 of the new or worsening signs and/or symptoms listed above AND must have at least 1 of the following complicating factors:

  • Obstructive uropathy
  • Congenital, functional, or anatomic abnormality of the urogenital tract
  • Temporary indwelling urinary catheter
  • Bladder instrumentation within <24 hours
  • Recurrent UTI (≥2 events within a 12-month period)
• Have a baseline urine culture specimen obtained within 48 hrs prior to the first dose of the study intervention. (Participants may be enrolled in this study and start i.v. study intervention therapy before the Investigator knows the results of the baseline urine culture in the event the causative pathogen is suspected to be susceptible to cefepime-enmetazobactam).

Specimen is to be obtained by suprapubic aspiration, clean intermittent urethral catheterization, indwelling urethral catheter, or mid- stream clean catch.

• Likely to survive the current illness or hospitalization.
• Sufficient intravascular access (peripheral or central) to receive study intervention

Exclusion Criteria:

• History of serious allergy, hypersensitivity (e.g., anaphylaxis), or any serious reaction to cefepime, any cephalosporin, penicillins, β-lactamase inhibitors (e.g., tazobactam, sulbactam, or clavulanic acid), or other β-lactam agents.
• Previous enrolment in this study, or in another interventional study ≤30 days before i.v. administration of study intervention.
• Concurrent infection requiring systemic antibiotics in addition to the i.v. study intervention therapy at the time of first study intervention administration.
• Receipt of systemic antibiotics within 24 hours before obtaining the study qualifying pre-treatment baseline urine sample and before study intervention therapy. Exceptions are:

• Receipt up to 24 hours of short-acting antibacterial agent with a daily dose not completed. (Refer protocol ► Section 10.5, Appendix 5 for the list of allowed and disallowed antibiotics).

  • Patients who received prior antimicrobial therapy for the current cUTI/AP, and 1) in the Investigator's opinion, failed that prior antibiotic therapy (i.e., presented with worsening signs and symptoms), AND 2) were documented that the pathogen is non-susceptible to the prior antibiotic therapy.
  • Patients who have received antimicrobial prophylaxis for recurrent cUTI and then presented signs and symptoms consistent with an active new cUTI or AP.
• A permanent indwelling bladder catheter or instrumentation including nephrostomy or current urinary catheter or anticipation of urinary catheter placement that would not be removed during the course of i.v. study intervention therapy administration.
• Participant has suspected or known complete obstruction of any portion of the urinary tract, perinephric abscess, or ileal loops.
• Participant has trauma to the pelvis or urinary tract.
• Participant has undergone renal transplantation.
• Participant has a condition or history of any illness that, in the opinion of the investigator, would have made the participant unsuitable for the study (e.g., may have confounded the results of the study or posed additional risk in administering the study therapy to the participant).
• Participant is considered unlikely to survive the 6-week study period or had a rapidly progressive illness, including septic shock, that was associated with a high risk of mortality.
• At the time of first study intervention administration, known presence of a cUTI caused by pathogens resistant to Cefepime - enmetazobactam.

• Presence of any of the following clinically significant laboratory abnormalities:

  1. Haematocrit <25% or haemoglobin <8 g/dL (<80 g/L, <4.9 mmol/L) for children ≥ 1 month, or <13 g/dL (<130 g/L, <8.0 mmol/L) for children < 1 month.
  2. Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST)>3 times the age-specific upper limit of normal (ULN), or total bilirubin >2 times ULN (except known Gilbert's disease) and Absolute Neutrophil count<1000/ mm3.
  3. eGFR <30 mL/min/1.73m2. (updated creatinine-based "Bedside Schwartz" equation (Schwartz et al. 2009))
• Participant has baseline QTcB (corrected Bazett's formula) of greater than 450 msec.
• History of seizures, excluding well-documented febrile seizures of childhood.
• If female, currently pregnant or breast feeding.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: cefepime and enmetazobactam unique study arm; Each study participant will receive a two-hour intravenous administration of cefepime and enmetazobactam every 8 hours, as single drug in fixed dose combination (FDC) formulation at a ratio of 4 to 1.	Drug: cefepime and enmetazobactam combination; Cefepime and enmetazobactam fixed dose combination administered intravenously every 8 hours as single drug formulation; Other Names: cefepime-enmetazobactam

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pharmacokinetics Cmax	Maximum Plasma Concentration [Cmax] ; unit= mg/L	Day 1 - Day 2
Pharmacokinetics Tmax	Time to reach Cmax (Tmax) ; unit= h	Day 1 - Day 2
Pharmacokinetics AUC0-tau	Area under the plasma concentration time curve from time zero to the end of the dosing interval (AUC0-tau) ; unit= mg.h/L	Day 1 - Day 2
Pharmacokinetics AUC0-inf	Area under the concentration time curve from time zero extrapolated to infinity (AUC0-inf) ; unit= mg.h/L	Day 1 - Day 2
Pharmacokinetics t1/2	Elimination half-life (t1/2), apparent terminal elimination rate constant (λz) ; unit= h	Day 1 - Day 2
Pharmacokinetics CL & Vd	Clearance (CL, volume of plasma cleared of the drug per unit time) ; unit= L, Volume of distribution (Vd) ; unit= L	Day 1 - Day 2
Pharmacokinetics Cmin	Trough observed plasma concentration (Cmin) ; unit= mg/L	Day 1 - Day 2
Safety and Tolerability	Patients with treatment emergent adverse events (AE); unit=percentage	before 1st study intervention until EOT +28 Days (±5 Days)
Safety and Tolerability	Patients with drug related related treatment emergent (AE); unit=percentage	before 1st study intervention until EOT +28 Days (±5 Days)
Safety and Tolerability	Patients with study intervention discontinuation due to AE; unit=percentage	before 1st study intervention until EOT +28 Days (±5 Days)
Safety and Tolerability	Patients with serious adverse event (SAE); unit=percentage	before 1st study intervention until EOT +28 Days (±5 Days)
Safety and Tolerability	Patients with drug related serious adverse event; unit=percentage	before 1st study intervention until EOT +28 Days (±5 Days)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Efficacy assessment	Efficacy Overall success rate (Combined clinical and microbiological success rate); Clinical response; Microbiological response The main efficacy endpoint is the overall success rate (Combined clinical and microbiological success) in the m-MITT population at TOC. The other efficacy endpoints are listed below: Clinical response of cure at TOC in m-MITT population; Microbiological response of eradication at TOC in m-MITT population; Overall success rate at Day 3, end-of-therapy (EOT), LFU in m-MITT population; Clinical response rate at the Day 3, EOT, LFU visits in m-MITT population; Microbiological response rate at the Day 3, EOT, LFU visits in m-MITT population; Overall success rate at Day 3, EOT, TOC, LFU in Clinically Evaluable (CE) and in microbiologically evaluable (ME) populations; Clinical response rate at Day 3, EOT, TOC, LFU in CE and ME populations; Microbiological response at the Day 3, EOT, LFU visits in CE and ME populations	7 Days (±2 Days) after the end-of-therapy (EOT)

Collaborators and Investigators

• Sponsor: Allecra
• Collaborators: Linical Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): September 11, 2023
• Primary Completion (Estimated): September 30, 2025
• Study Completion (Estimated): March 30, 2026

Study Registration Dates

• First Submitted: January 30, 2023
• First Submitted That Met QC Criteria: April 21, 2023
• First Posted (Actual): April 24, 2023

Study Record Updates

• Last Update Posted (Actual): January 12, 2024
• Last Update Submitted That Met QC Criteria: January 11, 2024
• Last Verified: January 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Infections; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Urinary Tract Infections; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Enzyme Inhibitors; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cefepime; Enmetazobactam
• Other Study ID Numbers: AT-202

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No